Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also operates through SecureDose Synthetics Inc., which is a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.


CSE:PHRX - Post by User

Post by Guytoruleon Oct 31, 2024 7:50pm
102 Views
Post# 36291618

New debenture raise..to replace current debenture..!

New debenture raise..to replace current debenture..!Good news, just released new debenture raise to replace current outstanding debenture due. Conversion possible within 1 year at a share price of .05 cents. All good, and with other good news today with their sustainability result of their Sairiyo drug thats entering approved FDA clinical trial shortly, only brings heighten value to shareholders with raising share price...At .02/ share is a screaming buy currently and may definately be a multi-bagger return to investors.  Risk/Reward high. Accumulating at this current share price bottom is an opportunity, in my opinion. Good luck to everyone holding and accumulating share...
<< Previous
Bullboard Posts
Next >>